阿法替尼联合同步术后放疗治疗中高危头颈部鳞癌的I期研究
本研究为开放标签、多中心、两队列的I期剂量递增试验,采用3+3设计,评估阿法替尼联合术后放疗(PORT)用于中危头颈部鳞癌(SCCHN),以及阿法替尼联合PORT与每周多西他赛用于高危SCCHN的最大耐受剂量和耐受性。2013年4月至2017年11月共入组27例患者(中危16例,高危11例),因剂量限制性毒性(DLTs)未确定最大耐受剂量,主要毒性为3级黏膜炎。结论认为该方案因3级毒性(主要为黏膜炎)耐受性差,尤其在需高剂量照射口腔的患者中,可能更适合非口腔部位或调整给药方案。
要点
- 阿法替尼联合PORT在口腔为主的SCCHN中因3级黏膜炎等DLTs未确定最大耐受剂量。
- 中危臂DLTs为3级黏膜炎4例和3级腹泻2例,高危臂为3级黏膜炎3例和3级腹泻/低钾1例。
- 该方案可能更适合非口腔部位或不同给药方案,需进一步探索。
核心结论
- 阿法替尼联合术后放疗治疗黏膜SCCHN因3级毒性(主要为黏膜炎)耐受性差,未确定最大耐受剂量。
研究设计与样本
- 开放标签、多中心、两队列、I期剂量递增试验,采用3+3设计,共27例患者(中危16例,高危11例)。
- 入组患者为头颈部鳞癌(口腔、口咽、喉或下咽)根治术后具有中危或高危病理特征者。
- 阿法替尼在PORT前1周导入,PORT期间(6至6.5周)每日给药,联合或不联合每周多西他赛,起始剂量30 mg,可递增至40 mg或递减至20 mg。
主要发现
- 27例患者中25例为口腔癌,中危臂中位总剂量60 Gy,高危臂65 Gy。
- 出现1例4级事件,无死亡。
- 因两臂均出现剂量限制性毒性(DLTs),未确定最大耐受剂量。
- 高危臂DLTs为3级黏膜炎3例和3级腹泻/低钾血症1例;中危臂DLTs为3级黏膜炎4例和3级腹泻2例。
临床怎么用
- 阿法替尼联合术后放疗在需高剂量照射口腔的SCCHN患者中耐受性差,临床应用需谨慎选择患者。
- 对于非口腔部位或调整给药方案可能改善耐受性,值得进一步研究。
局限性
- 样本量小(27例),主要为口腔癌患者,结果外推受限。
- 未确定最大耐受剂量,无法推荐后续研究剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the maximum tolerated dose and tolerability of (1) afatinib in combination with postoperative radiation therapy (PORT) for patients with intermediate-risk squamous cell carcinoma of the head and neck (SCCHN) and (2) afatinib in combination with PORT and weekly docetaxel for high-risk SCCHN. METHODS AND MATERIALS: An open-label, multicenter, 2-cohort, phase 1 dose-escalation trial was conducted using a 3 + 3 design. Eligible patients had definitive surgery for SCCHN, including the oral cavity, oropharynx, larynx, or hypopharynx and had intermediate- or high-risk pathologic features. Afatinib was given for a 1-week lead in before PORT and daily during 6 to 6.5 weeks of PORT with or without weekly docetaxel. The starting dose was 30 mg and could be escalated to 40 mg or de-escalated to 20 mg. The primary objective was to determine the maximum tolerated dose of afatinib with PORT or PORT + docetaxel. RESULTS: Between April 2013 and November 2017, 27 patients were enrolled and started study treatment, including 16 intermediate-risk patients and 11 high-risk patients, all with Eastern Cooperative Oncology Group performance status of 0 to 1. Most patients (n = 25) had oral cavity cancer and were treated to a median total dose of 60 Gy in the intermediate-risk arm and 65 Gy in the high-risk arm. There was 1 grade 4 event, but no deaths. The maximum tolerated dose was not established owing to dose-limiting toxicities (DLTs) in both arms. In the high-risk arm, DLTs were grade 3 mucositis (n = 3) and grade 3 diarrhea/hypokalemia (n = 1). In the intermediate-risk arm, DLTs were grade 3 mucositis (n = 4) and grade 3 diarrhea (n = 2). CONCLUSIONS: Afatinib in combination with PORT for mucosal SCCHN was difficult to tolerate because of grade 3 toxicity, mostly mucositis, in a cohort of patients requiring high-dose PORT to the oral cavity. This regimen may be better tolerated for a non-oral cavity site or if given in a different schedule.
引用
- Margalit DN, Haddad RI, Tishler RB, et al. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019. PMID: 31082494. doi:10.1016/j.ijrobp.2019.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。